CN102028703A - New application of inulin - Google Patents

Abstract

The purpose of the present invention is to disclose the new application of inulin, that is, the new application of inulin in the preparation of medicines and health care products for preventing and treating hyperuricemia. The hyperuricemia also includes high uric acid combined with hypertriglyceridemia, high uric acid combined with hyperglycemia, high uric acid combined with high triglycerides, hyperglycemia, high uric acid combined with hypercoagulation and/or hyperviscosity blood disease etc. Inulin is highly safe when used to prevent and treat the above symptoms, and no obvious adverse reactions and side effects have been seen.

Description

New uses of inulin

technical field

The invention relates to a new application of inulin, which belongs to the technical field of traditional Chinese medicine.

Background technique

Hyperuricemia is a chronic purine metabolic disorder, which means that the urate saturation in the blood is about 70mg/L. The clinical diagnostic criteria for hyperuricemia are: ≥420 μmol/L (70 mg/L) for males and ≥360 μmol/L (60 mg/L) for females. Uric acid is the end product of purine metabolism. Due to the accelerated pace of human life and changes in dietary structure, people’s intake of sugar, fat, and protein has increased significantly. There is a clear upward trend. A large number of epidemiological studies in recent years have shown that the prevalence of hyperuricemia in my country is increasing year by year in all regions and age groups. According to preliminary statistics, the general incidence rate of hyperuricemia in my country is about 10%, that is, about 120 million people suffer from hyperuricemia. Hyperuricemia and related diseases caused by it seriously endanger people's health, and have become a major metabolic disease that seriously endangers human health in the 21st century.

As a storage polysaccharide of plants, inulin is mainly found in plants such as chicory, Jerusalem artichoke and dahlia. Inulin has the general biological characteristics of polysaccharides, such as promoting the proliferation of beneficial bacteria, reducing the pathogenicity of pathogenic bacteria, regulating the body's immune system, and improving host immunity. In addition, inulin is hardly hydrolyzed and digested by gastric acid during human digestion and absorption, and is fermented by a large number of beneficial microorganisms when it reaches the colon, and has the characteristics of fructooligosaccharides and dietary fiber. Adding inulin to food can significantly improve the sensory properties of food; scientific research shows that inulin can increase calcium absorption by nearly 20%, which is helpful to improve human health; inulin can also be used in low-fat spreads containing milk protein Among them, it is a good fat substitute; inulin can also reduce liver toxicity, generate anti-cancer organic acids in the intestines, have significant anti-cancer functions, and have preventive and therapeutic effects on breast cancer and colon cancer. So far, there are no reports about inulin lowering uric acid and related complications at home and abroad.

Studies have shown that the characteristic of inulin is that it can significantly reduce the blood uric acid level of hyperuricemia model animals (rats, mice, quails). And other metabolic diseases have a good regulatory effect. Based on a large number of experimental studies on inulin, the research group believes that inulin can regulate the body's glycolipidoprotein metabolism disorder, and its pharmacological effects have the advantages of multiple aspects and multiple targets. Further in-depth research can develop it into health care products, medicines and functional foods with the functions of lowering uric acid, lowering triglycerides, lowering blood sugar and its complications. In addition, inulin has a good effect on improving the pathological changes of model animals with hyperuric acid and hypertriglyceridemia and/or hyperglycemia. It can significantly reduce blood uric acid, blood lipids, and blood sugar levels; Hypercoagulability and/or hyperviscosity complicated by hypercoagulation and/or hyperviscosity have a good improvement effect, and can significantly regulate hemorheological changes and plasmin activity.

Invention content:

The purpose of the present invention is to disclose the application of inulin in the preparation of drugs for preventing or treating hyperuricemia and its complicated blood lipids, blood sugar and other multiple metabolic disorders, health care products or functional foods.

The inulin described in the present invention is a linear structure fructan.

The inulin is a straight-chain structure fructan with a glucose residue (G) at the end of the fructose residue (F); or a straight-chain structure fructan with a glucose residue at the end of the fructose residue (F) A mixture of sugar and a straight-chain structure fructan not connected with a glucose residue; or a straight-chain structure fructan not connected with a glucose residue at the end of a fructose residue (F).

The straight chain structure fructan with a glucose residue at the end of the fructose residue (F) is composed of furan-configured D-fructose via a β-2,1 glycosidic bond dehydration polymer, and the fructose residue ( F) A linear polysaccharide with a glucose residue (G) attached to the end.

The DP (polymerization degree) value variation range of described inulin is 2～60, and average DP value is 9～12;

The weight average molecular weight of the inulin ranges from 1.00×10 ³ to 10.00×10 ³ , and the distribution is preferably 2.07×10 ³ to 9.34×10 ³ ;

The purity of the inulin is more than 70% (content of fructan), preferably more than 90% of purity (content of fructan);

The content of monosaccharide and disaccharide in the inulin is 5-10%;

The ash content of the inulin is ≤0.2%; its taste is neutral, slightly sweet or has no sweet taste.

The invention provides the application of the above-mentioned inulin in the preparation of medicine for treating hyperuricemia.

The invention provides the application of the above-mentioned inulin in the preparation of a medicine for treating hyperuricemia complicated with hyperglycemia.

The invention provides the application of the above-mentioned inulin in the preparation of medicines for treating hyperuricemia combined with hyperglycemia and hypertriglyceridemia.

The invention provides the application of the above-mentioned inulin in the preparation of a medicine for treating hyperuricemia combined with hypertriglyceridemia.

The present invention provides the application of the above-mentioned inulin in the preparation of medicaments for reducing uric acid levels.

The present invention provides the application of the above-mentioned inulin in the preparation of drugs for treating and lowering blood sugar.

The present invention provides the application of the above-mentioned inulin in the preparation of medicines for reducing TC (total cholesterol).

The present invention provides the application of the above-mentioned inulin in the preparation of medicines or health products for regulating hyperuricemia and hypercoagulation and/or hyperviscosity, specifically refers to the use of inulin in the preparation of reducing hyperuricemia and hypertriglyceridemia Whole blood viscosity and/or the application of drugs for improving fibrinolytic activity; the improvement of inulin on the state of hypercoagulation and hyperviscosity is achieved by regulating blood rheology and plasmin activity.

In this study, a variety of hyperuricemia animals (rats, mice, quails) were used as experimental subjects to study the effect of inulin on the blood uric acid level of hyperuricemia, and found that inulin can significantly reduce the blood uric acid level . At the same time, inulin can also reduce the level of uric acid in animals with hyperuricemia, reduce the levels of uric acid and blood sugar in animals with hyperuricemia combined with hyperglycemia, and reduce the levels of uric acid in animals with hyperuricemia combined with hyperglycemia and hypertriglyceridemia. Effect of blood glucose and triglyceride levels. Inulin does not affect animal liver and kidney function.

The following experimental examples and examples are used to further illustrate the present invention.

Effect of Experimental Example 1 Inulin on Hyperuricemia in Mice

1. Drugs

Inulin is a mixture of straight-chain structure fructans with a glucose residue at the end of a straight-chain structure fructose residue (F) and a small amount of straight-chain structure fructans without a glucose residue; the weight average of inulin The molecular weight ranges from 2.07×10 ³ to 9.34×10 ³ ; the purity (fructan content) is above 90 percent; and the inulin monosaccharide and disaccharide content is 5-10 percent.

2. Method:

Kunming mice, male, weighing 18g-22g. According to body weight, they were randomly divided into normal group, model group, positive drug benzbromarone group, high-dose inulin treatment group, medium-dose inulin treatment group, and low-dose inulin treatment group, with 10 rats in each group. The normal group was given normal feed, and the rest of the groups were given hyperuricemia modeling feed (feeding uric acid and uricase inhibitors). Dosage and method of administration: The positive drug group was given benzbromarone by intragastric administration, the large, medium and small inulin dose groups were given intragastric administration of inulin aqueous solution, and the normal group and model group were given intragastric administration with equal volume of water for 14 consecutive days. On the 13th day of the experiment, the animals were fasted for 12 hours without food and water. The next day, the animals were decapitated to take blood, centrifuged at 3000 rpm for 15 minutes, and the serum was separated. The levels of various indicators in the serum were measured with an automatic biochemical analyzer.

Experimental results:

1. The effect on the level of uric acid in mice, the results are shown in Table 1.

±s)Table 1 Comparison of serum UA levels of mice in each group on the 14th day of the experiment (

±s)

Compared with normal group: ***P<0.001 Compared with model group: ##P<0.01, ###P<0.001

The results showed that, compared with the normal group, the serum UA level of the animals in the model group was significantly increased (P<0.001); The low-dose groups all had the effect of significantly reducing the uric acid level in hyperuricemia model mice (P<0.001, P<0.01, P<0.01, P<0.001). It can be seen from the above experimental result 1 that different doses of inulin have different curative effects on hyperuricemia.

2. The effect on mouse serum GLU and TG, the results are shown in Table 2.

±s)Table 2 The comparison of serum GLU and TG levels of mice in each group on the 14th day of the experiment (

±s)

Compared with normal group: *P<0.05 Compared with model group: #P<0.05

The results showed that: compared with the normal group, the serum GLU level of the animals in the model group was significantly increased (P<0.01); Significantly decreased (both P<0.05); compared with the normal group, the serum TG (triglyceride) level of the model group was significantly increased (P<0.01); compared with the model group, the benzbromarone group, inulin Serum TG levels in the low-dose group were significantly reduced (all P<0.05).

From the above experimental results 1 and 2, it can be seen that different doses of inulin have different curative effects on hyperuricemia combined with hyperglycemia, hyperuricemia combined with hyperglycemia and hypertriglyceridemia.

3. The effect on mouse serum TC, the results are shown in Table 3.

±s)Table 3 Comparison of serum TC levels of mice in each group on the 14th day of the experiment (

±s)

Compared with the model group: #P<0.05, ##P<0.01

The results show that:

Compared with the normal group, the serum TC (total cholesterol) of the animals in the model group only had a tendency to increase without significant difference; compared with the model group, the serum TC levels of the medium-dose inulin group and the low-dose inulin group decreased significantly (P <0.01, P<0.05)

4. The impact on the renal function of mice, the results are shown in Table 4.

±s)On the 14th day of the experiment in table 4, the renal function levels of mice in each group were compared (

±s)

Compared with normal group: *P<0.05, **P<0.01

Compared with the model group: #P<0.05

The results showed that: compared with the normal group, the serum BUN level of the model group was significantly increased after 14 days of treatment (P<0.01). Compared with the model group, the serum BUN level of the high-dose inulin treatment group was significantly lower (P<0.05), and there was no significant difference in other cases. Compared with the normal group, the serum Cre level of the model group was significantly increased after 14 days of treatment (P<0.05). Compared with the model group, there was no significant difference in the serum Cre levels of each administration group. From the above experimental results, it can be seen that different doses of inulin do not affect the liver and kidney functions of mice.

5. The effect on the body weight of mice, the results are shown in Table 5.

±s)Comparison of mouse body weight levels on the 14th day of the experiment in table 5 (g,

±s)

The results showed that during the experiment period, the animals in each group were in good growth condition, and their hair color and spirit were good.

There was no significant difference in body weight among the groups.

Effect of Experimental Example 2 Inulin on Hyperuricemia in Rats

1. Drugs

Inulin is a mixture of straight-chain structure fructans with a glucose residue attached to the end of a straight-chain structure fructose residue (F) and a small amount of straight-chain structure fructans without a glucose residue; the weight average of inulin The molecular weight ranges from 2.07×10 ³ to 9.34×10 ³ ; the purity (fructan content) is above 90 percent; and the inulin monosaccharide and disaccharide content is 5-10 percent.

2. Method:

50 male SD rats were randomly divided into 5 groups: normal group, model group, positive drug benzbromarone group, high-dose inulin group, and low-dose inulin group, with 10 rats in each group. The normal group was given normal feed, and the other groups were given fructose feed. At the same time, the yang drug group was given intragastric administration of fenofibrate, the high-dose and small-dose groups of inulin were given intragastric administration of inulin aqueous solution, and the normal group and model group were given intragastric administration of equal volume of water for 7 consecutive days. In the evening of the sixth day of the experiment, the animals were fasted for 12 hours, and 2 ml of blood was collected from the tail vein on the next day, centrifuged, and the serum was separated, and the contents of various indicators in the serum were measured with an automatic biochemical analyzer.

Experimental results:

1. The effect on UA level in rats, the results are shown in Table 6.

±s)Table 6 The comparison of UA levels in rats in each group on the 7th day of the experiment (

±s)

Compared with normal group: **P<0.01 Compared with model group: #P<0.05

The results showed that: compared with the normal group, the serum UA level of the model group was significantly increased on the 7th day of the animal experiment (P<0.01); compared with the model group, the serum UA level of the fenofibrate and inulin high-dose groups was significantly reduced ( All P<0.05). From the above experimental results 6, it can be seen that inulin has different degrees of curative effect on hyperuricemia in rats.

2. The effects on Glu and TG levels in rats, the results are shown in Table 7.

±s)On the 7th day of the experiment in table 7, the Glu and TG levels of rats in each group were compared (

±s)

Compared with normal group: *P<0.05

Compared with the model group: ###P＜0.001

The results show that:

Compared with the normal group, the serum TG level of the animal experiment in the model group was significantly increased on the 7th day (P<0.05); compared with the model group, the serum TG level of the fenofibrate group, inulin large and small dose groups was significantly reduced ( All P<0.001). On the seventh day of the experiment, there was no significant change in serum Glu levels.

From the above experimental results 6 and 7, it can be seen that different doses of inulin have different curative effects on hyperuricemia combined with hypertriglyceridemia.

3. The effect on rat liver and kidney function, the results are shown in Table 8. (n=10, ±s)

Table 8 Comparison of liver and kidney function levels of rats in each group on the 7th day of the experiment

Compared with the normal group, the levels of GOT, GPT, BUN and CRE in the serum of animals in the model group had no significant changes on the 7th day after administration. Compared with the model group, the levels of serum GOT, GPT, BUN, and CRE in each group had no significant changes; the levels of GOT and GPT in the large and low dose groups of inulin had no significant changes. According to the experimental results of liver and kidney function in rats, it can be seen that each dose group of inulin does not affect the liver and kidney function of rats.

4. The impact on the body weight of rats, the results are shown in Table 9.

±s)Table 9 experiment the 7th day rat body weight level comparison (g,

±s)

Compared with the model group: #P<0.05 ##P<0.01

The results showed that: compared with the model group, the body weight of the rats in the fenofibrate group and the large amount of inulin group was significantly lower (P<0.01, P<0.05, respectively). It can be seen that the high-dose inulin group can reduce the body weight of animals in the state of high TG, and the low-dose inulin has no obvious effect on the body weight.

Experimental Example 3 Effect of Inulin on Quail Hyperuricemia

1. Drugs

Inulin is a mixture of straight-chain structure fructans with a glucose residue at the end of a straight-chain structure fructose residue (F) and a small amount of straight-chain structure fructans without a glucose residue; the weight average of inulin The molecular weight ranges from 2.07×10 ³ to 9.34×10 ³ ; the purity (fructan content) is above 90 percent; and the inulin monosaccharide and disaccharide content is 5-10 percent.

2. Method:

Sixty Difac quails, male, weighing 170±10g, were randomly divided into normal group, model group, positive drug benzbromarone group, high-dose inulin group, and low-dose inulin group according to body weight, with 12 quails in each group. The normal group was given normal feed, and the other groups were given modeling feed containing yeast extract powder, and the animals in each group were free to eat and drink. Dosage and method of administration: The positive drug group was given benzbromarone by intragastric administration, and the inulin water solution was administered by intragastric administration to the groups with large and small doses of inulin. The normal group and the model group were fed with equal volume of water for 14 consecutive days. On the thirteenth day of the experiment, food and water were fasted for 12 hours in the evening, and blood was collected from the jugular vein in the morning of the next day, centrifuged, and serum was separated, and the serum was detected by an automatic biochemical analyzer.

Experimental results:

1. The effect on the UA level in quail serum, the results are shown in Table 10

±s)Table 10 experiment the 14th day each group quail serum UA level comparison (

±s)

Compared with normal group: **P<0.01 Compared with model group: #P<0.05, ##P<0.01

The results show that:

Compared with the normal group, the serum UA level of the quail in the model group was significantly increased on the 14th day of the experiment (P<0.01).

Compared with the model group, the serum UA level of the positive control drug benzbromarone group decreased significantly on the 14th day (P<0.05); the serum UA level of the high-dose inulin group decreased significantly on the 14th day (P<0.05); The serum UA level of the dose group decreased significantly on day 14 (P<0.01).

It can be seen from the above experimental results 10 that different doses of inulin have different curative effects on quail hyperuricemia.

2. The effects on quail serum Glu and TG levels, the results are shown in Table 11.

Table 11 The comparison of Glu, TG, and TC levels in quail serum of each group on the 14th day of the experiment ( ±s)

The results showed that there was no significant difference in serum Glu levels of quails in each group during the experiment

Compared with the normal group, the serum TG level of the quails in the model group had a tendency to increase on the 14th day and no significant difference was found; compared with the model group, the serum TG level of the benzbromarone group had a tendency to decrease on the 14th day and no significant difference was found . There was no significant difference in the decreasing trend of serum TG levels between the high-dose inulin group and the low-dose group on the 14th day.

Compared with the normal group, there was no significant difference in the serum TC level of the model group quails on the 14th day;

Compared with the model group, there was no significant difference in serum TC levels in each medication group.

4. The effect on quail liver function and kidney function, the results are shown in Table 12.

±s  n＝12)Table 12 Experiment 14th day each group quail liver function, kidney function level comparison (

±sn=12)

Compared with the model group, #P＜0.05

The results showed that compared with the normal group, there was no significant difference in GOT, GPT, CRE, and BUN of the quail in the model group. Compared with the normal group, the serum BUN level of quails in the benzbromarone group was significantly increased (P<0.05), and there was no significant difference in other indexes. From the above experimental results, it can be seen that each dose group of inulin has no significant effect on the liver and kidney functions of quail.

5. The effect on the body weight of quail, the results are shown in Table 13.

±s)Quail body weight level comparison (g,

±s)

The results showed that during the experiment period, the animals in each group were in good growth condition, and their hair color and spirit were good. There was no significant difference in body weight among the groups.

Experimental example 4 Effect of inulin on hemorheology of quail hyperuricemia and hypertriglyceridemia model

1. Drugs

Inulin is a mixture of straight-chain structure fructans with a glucose residue at the end of a straight-chain structure fructose residue (F) and a small amount of straight-chain structure fructans without a glucose residue; the weight average of inulin The molecular weight ranges from 2.07×10 ³ to 9.34×10 ³ ; the purity (fructan content) is above 90 percent; and the inulin monosaccharide and disaccharide content is 5-10 percent.

2. Method:

60 Difac quails, weighing 170±10g, were randomly divided into normal group, model group, positive drug benzbromarone group, inulin large, medium and small dose groups, 10 in each group. The normal group was given normal feed, and the rest of the groups were given modeling feed containing yeast extract powder, and the animals in each group had free access to water. Dosage and method of administration: The positive drug group was given benzbromarone by intragastric administration, and the inulin water solution was administered by intragastric administration to the groups with large and small doses of inulin. The normal group and the model group were fed with equal volume of water for 7 consecutive days. On the 6th day of the experiment, fasting without food and water for 12 hours in the evening, blood was collected from the jugular vein in the morning of the next day, centrifuged, and the serum was separated, and the serum was detected by an automatic biochemical analyzer.

1. The effect on the viscosity of quail whole blood, the results are shown in Table 14.

±s)Table 14 experiment the 7th day each group quail whole blood viscosity level comparison (

±s)

Compared with the normal group, *p<0.05,

Compared with the model group, #p<0.05, ##p<0.01, ###p<0.001

The results showed that: compared with the normal group, the whole blood viscosity of the model group was significantly increased at each shear rate, and the difference was significant (p<0.05). Compared with the model group, the whole blood viscosity in the large, medium and small dose groups of inulin decreased significantly at shear rates of 200(1/s), 30(1/s), and 5(1/s) (P< 0.05～0.001), the whole blood viscosity at the shear rate of 1 (1/s) also showed a decreasing trend; the whole blood viscosity of Yangzhao medicine at the shear rate of 200 (1/s), 30 (1/s) It was also significantly reduced (P<0.05), and there was no significant difference compared with the various dosage groups of inulin.

2. The effect on quail plasma viscosity, erythrocyte sedimentation rate and HCT, the results are shown in Table 15.

±s)Table 15 experiment the 7th day each group quail plasma viscosity, erythrocyte sedimentation rate, HCT level comparison (

±s)

Compared with the normal group, *p<0.05, **p<0.01

Compared with the model group, #p<0.05, ##p<0.01, ###p<0.001

The results showed that: compared with the normal group, the plasma viscosity, erythrocyte sedimentation rate and HCT of the model group were significantly increased, the difference was significant (P<0.05～P<0.01). Compared with the model group, the plasma viscosity and HCT of the large, medium and small dose groups of inulin were significantly reduced (p<0.05-0.001); the plasma viscosity and HCT of the positive medicine group were significantly reduced (p<0.05-0.01), Compared with the inulin medication group, there was no difference, and the erythrocyte sedimentation rate values of each medication group had a downward trend.

3. Effects on quail red blood cell deformability and red blood cell aggregation, the results are shown in Table 16.

±s)Table 16 experiment the 7th day each group quail erythrocyte deformability, erythrocyte aggregation level comparison (

±s)

Compared with the normal group, *p<0.05,; compared with the model group, #p<0.05,

The results showed that: compared with the normal group, the erythrocyte aggregation index of the model group quail was significantly higher than that of animals (P<0.05); while the erythrocyte deformation index was significantly lower than that of the normal group animals (P<0.01). Compared with the model group, the erythrocyte deformation index of the Yang medicine group, large, medium and small doses of inulin groups were all significantly increased (P<0.05-0.01), and the effect of increasing the erythrocyte deformation index of the middle dose group of inulin was better than that of the model group. Positive control drug (P<0.05); at the same time, the high-dose inulin group can also significantly reduce the aggregation index of red blood cells (P<0.05).

4. The effect on quail plasma FIB content, PLG level and PL activity, the results are shown in Table 17.

Table 17 Comparison of quail plasma FIB content, PLG level and PL activity level in each group on the 7th day of the experiment

Compared with the normal group, *p<0.05, **p<0.01, ***p<0.001

Compared with the model group, #p<0.05, ##p<0.01, ###p<0.001

The results showed that: compared with the normal group, the FIB content and PLG level in the model group were significantly increased (P<0.01-0.001), and the PL activity was significantly decreased (P<0.05). Compared with the model group, the Yang medicine group, large, medium and small doses of inulin groups could significantly reduce the plasma FIB content (P<0.05-0.001), among which, the effect of large and medium doses was the best. The dose group can also significantly reduce the PLG level (P<0.05-0.01), and the medium and small doses can increase the PL activity (P<0.05).

From the above experimental results, it can be seen that inulin has a good improvement effect on the pathological changes in the condition of hyperuricemia and hypertriglyceridemia, and it can have a good improvement effect on blood rheology and fibrinolytic activity. Inulin can significantly reduce the whole blood viscosity of quail with high uric acid and hypertriglyceridemia. From the experimental results, we can see that the improvement effect of inulin on whole blood viscosity is through its effect on plasma viscosity, HCT, red blood cell deformability and aggregation. performance improvement. Inulin can significantly improve the abnormal fibrinolytic activity, which is closely related to the increase of PL activity, thereby reducing the FIB content in blood. At the same time, because inulin can also reduce the content of UA and TG in the blood, it is speculated that its improvement on the fibrinolytic system may also be related to its effect on the metabolism of UA and TG.

The following embodiments can all achieve the effects of the above experimental examples.

Detailed ways

Example 1:

Main drug: inulin, which is a straight-chain structure fructan with a glucose residue attached to the end of the fructose residue (F), which is composed of furan-configured D-fructose via β-2,1 glycosidic bond dehydration polymer, and A linear polysaccharide with a glucose residue (G) attached to the end of the fructose residue (F); the weight average molecular weight ranges from 2.07×10 ³ to 9.34×10 ³ ; the purity (fructan content) is above 80% ; The content of the inulin monosaccharide and disaccharide is 7%.

Excipients: Lactose

Add lactose equivalent to 30% of its weight to the above inulin, and make inulin granules by conventional methods.

Example 2:

Main drug: inulin, which is a linear structure fructan without a glucose residue at the end of the fructose residue (F), with a weight average molecular weight ranging from 2.07×10 ³ to 9.34×10 ³ ; the purity (the content of fructan) is over 93%; the content of the inulin monosaccharide and disaccharide is 8%.

Excipients: lactose (starch, dextrin, powdered sugar, lactose, mannitol, sorbitol, etc. are well formed)

The above inulin is added with lactose equivalent to 30% of its weight, and then a lubricant magnesium stearate is added, and the inulin tablet is obtained by compression in a conventional method.

Example 3:

Main drug: inulin, which is a straight-chain structure fructan with a glucose residue at the end of the fructose residue (F) and a straight-chain structure fructan without a glucose residue The weight-average molecular weight of the mixture ranges from 2.07×10 ³ to 9.34×10 ³ ; the purity (content of fructan) is over 93 percent; and the content of the inulin monosaccharide and disaccharide is 8 percent.

Excipients: Lactose

The above inulin is added with lactose equivalent to 30% of its weight, and then CMC-Na with a total volume of 2‰～5‰ of the liquid is added, and the inulin oral liquid is prepared by a conventional method.

Example 4:

Main drug: inulin, which is a straight-chain structure fructan with a glucose residue attached to the end of the fructose residue (F), which is composed of furan-configured D-fructose via β-2,1 glycosidic bond dehydration polymer, and A linear polysaccharide with a glucose residue (G) attached to the end of the fructose residue (F); the weight average molecular weight ranges from 2.07×10 ³ to 9.34×10 ³ ; the purity (fructan content) is above 92% ; The content of the inulin monosaccharide and disaccharide is 8%.

Excipients: Lactose

The above inulin is added with lactose equivalent to 30% of its weight, and the granules are prepared by conventional methods and then packed into capsules to make inulin capsules.

Example 5:

Main drug: inulin, which is a straight-chain structure fructan with a glucose residue attached to the end of the fructose residue (F), which is composed of furan-configured D-fructose via β-2,1 glycosidic bond dehydration polymer, and A linear polysaccharide with a glucose residue (G) attached to the end of the fructose residue (F); the weight average molecular weight ranges from 2.07×10 ³ to 9.34×10 ³ ; the purity (fructan content) is above 92% ; The content of the inulin monosaccharide and disaccharide is 6.

Excipients: Starch

The above-mentioned inulin is added with starch corresponding to 30% of its weight, and the capsules are prepared by a conventional method.

Embodiment 6:

Main drug: inulin, which is a straight-chain structure fructan with a glucose residue attached to the end of fructose residue (F), which is composed of D-fructose in furan configuration through β-2,1 glycosidic bond dehydration polymer, and A linear polysaccharide with a glucose residue (G) attached to the end of the fructose residue (F); the weight average molecular weight ranges from 2.07×10 ³ to 9.34×10 ³ ; the purity (fructan content) is above 92% ; The content of the inulin monosaccharide and disaccharide is 6. Inulin ash content ≤ 0.2%; its taste is neutral, slightly sweet or not sweet.

Excipients: dextrin

Add dextrin equivalent to 30% of its weight to the above inulin, and make capsules by conventional methods.

Embodiment 7:

Main drug: inulin, which is a straight-chain structure fructan with a glucose residue attached to the end of the fructose residue (F), which is composed of furan-configured D-fructose via β-2,1 glycosidic bond dehydration polymer, and A linear polysaccharide with a glucose residue (G) attached to the end of the fructose residue (F); the weight average molecular weight ranges from 2.07×10 ³ to 9.34×10 ³ ; the purity (fructan content) is above 92% ; The inulin monosaccharide and disaccharide content is 9 inulin ash content ≤ 0.15 and the taste is neutral, slightly sweet or not sweet.

Excipients: Mannitol

The above inulin is added with mannitol equivalent to 10% of its weight, and a capsule is prepared by a conventional method.

Embodiment 8:

Main drug: inulin, which is a straight-chain structure fructan with a glucose residue attached to the end of the fructose residue (F), which is composed of furan-configured D-fructose via β-2,1 glycosidic bond dehydration polymer, and A linear polysaccharide with a glucose residue (G) attached to the end of the fructose residue (F); the weight average molecular weight ranges from 2.07×10 ³ to 9.34×10 ³ ; the purity (fructan content) is above 92% ; The content of the inulin monosaccharide and disaccharide is 6. Inulin ash content ≤ 0.2%; its taste is neutral, slightly sweet or not sweet.

Excipients: Sorbitol

The above inulin is added with sorbitol equivalent to 10% of its weight, and a capsule is prepared by a conventional method.

Claims (10)

1. the application of inulin in preparation control antihyperuricemic disease drug or health product, the content of levan that has linear chain structure in the described inulin is more than 70%.

2. inulin merges application in high sugar and/or the hypertriglyceridemia medicine at preparation control metabolic arthritis, and the content of levan that has linear chain structure in the described inulin is more than 70%.

3. inulin is prevented and treated hyperuricemia in preparation and is merged anticoagulant and/or the medicine of high blood viscosity or the application in the health product, and the content of levan that has linear chain structure in the described inulin is more than 70%.

4. the application of inulin in preparation uric acid reducing medicine or health product, the content of levan that has linear chain structure in the described inulin is more than 70%.

5. inulin is prevented and treated medicine that hyperuricemia merges high T-CHOL or the application in the health product in preparation, and the content of levan that has linear chain structure in the described inulin is more than 70%.

6. as described any one application of claim 1-5, it is characterized in that inulin is that the linear chain structure levan is connected with a glucose residue at the residue of fructose end; Or be residue of fructose end linear chain structure levan that is connected with a glucose residue and the mixture that is not connected with the linear chain structure levan of a glucose residue.

7. application as claimed in claim 6, it is characterized in that linear chain structure levan that the residue of fructose end is connected with a glucose residue for by the D-fructose of furan configuration through β-2,1 glycosidic bond dehydrated polymer is formed, and is connected with the linear chain structure polysaccharide of a glucose residue at the residue of fructose end.

8. application as claimed in claim 6 is characterized in that described levan degree of polymerization value excursion is 2～60; Average DP value is 9～12; Monosaccharide and disaccharidase content are 5-10%.

9. application as claimed in claim 6, the weight average molecular weight range that it is characterized in that described inulin is 1.00 * 10 ³～10.00 * 10 ³

10. application as claimed in claim 6, the content of levan that it is characterized in that having in the described inulin linear chain structure is more than 90%.